Advances in Bacteriophage Therapy against Relevant MultiDrug-Resistant Pathogens
The increase of multiresistance in bacteria and the shortage of new antibiotics in the market is becoming a major public health concern. The World Health Organization (WHO) has declared critical priority to develop new antimicrobials against three types of bacteria: carbapenem-resistant <i>A....
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
MDPI AG,
2021-06-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The increase of multiresistance in bacteria and the shortage of new antibiotics in the market is becoming a major public health concern. The World Health Organization (WHO) has declared critical priority to develop new antimicrobials against three types of bacteria: carbapenem-resistant <i>A. baumannii</i>, carbapenem-resistant <i>P. aeruginosa</i> and carbapenem-resistant and ESBL-producing <i>Enterobacteriaceae</i>. Phage therapy is a promising alternative therapy with renewed research in Western countries. This field includes studies in vitro, in vivo, clinical trials and clinical cases of patients receiving phages as the last resource after failure of standard treatments due to multidrug resistance. Importantly, this alternative treatment has been shown to be more effective when administered in combination with antibiotics, including infections with biofilm formation. This review summarizes the most recent studies of this strategy in animal models, case reports and clinical trials to deal with infections caused by resistant <i>A. baumannii</i>, <i>K. pneumoniae</i>, <i>E. coli,</i> and <i>P. aeruginosa</i> strains, as well as discusses the main limitations of phage therapy. |
|---|---|
| Item Description: | 10.3390/antibiotics10060672 2079-6382 |